Page 271 - 2021_04-Haematologica-web

Letters to the Editor
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France, a co-primary investigator of the ICARIA-MM study, for reviewing this manuscript. We thank Medha Sasane, Wahidullah Noori and Denise Bury for their contributions to the Patient Reported Outcomes and Health-Related Quality of Life data collection and inter- pretation. Medical writing support was provided by Camile Semighini Grubor, PhD of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services.
Funding: the ICARIA-MM study was sponsored by Sanofi.
References
1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019. Accessed December 16, 2019.
2. Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K. Multiple myeloma in the very elderly patient: challenges and solu- tions. Clin Interv Aging. 2016;11:423-435.
3. Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980-987.
4. Dimopoulos MA, Kastritis E, Delimpasi S, et al. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur J Haematol. 2012;89(1):10-15.
5. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel human- ized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hemato- logic malignancies. Clin Cancer Res. 2014;20(17):4574-4583.
6. Jiang H, Acharya C, An G, et al. SAR650984 directly induces multi- ple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399-408.
7. Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myelo- ma. Clin Cancer Res. 2019;25(10):3176-3187.
8. Sanofi. SARCLISA [Package Insert]. Bridgewater, NJ 2020.
9. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus poma- lidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-
label, phase 3 study. Lancet. 2019;394(10214):2096-2107.
10. Richardson PG, Attal M, Campana F, et al. Isatuximab plus poma- lidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA phase III study
design. Future Oncol. 2018;14(11):1035-1047.
11. Anderson KC. Insights into the management of older patients with
multiple myeloma. Clin Adv Hematol Oncol. 2019;17(7):390-392. 12. van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in
multiple myeloma: back to the future. Blood. 2018;131(1):13-29. 13. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International
Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
haematologica | 2021; 106(4)
1187